EGFR positive

This integrative analysis characterized the ribociclib pharmacokinetic and exposure-QTcF relationship, revealed the population effect on both pharmacokinetic and QTcF response, and justified the 400-mg dose in EBC. This work illustrates the utility and impact of quantitative pharmacology in justifying different doses across different patient populations for oncology therapies.

We present the case of a 60-year-old non-smoking woman previously treated for luminal B human epidermal growth factor receptor 2 (HER2)-positive invasive breast carcinoma with surgery, AC60 chemotherapy, trastuzumab, breast radiotherapy, and hormone therapy at the Mohammed VI Oncology Center in Casablanca, Morocco. The patient received neoadjuvant vinorelbine-cisplatin chemotherapy followed by volumetric modulated arc therapy (VMAT) thoracic radiotherapy at 66 Gy, achieving clinical and radiological stabilization. This case highlights the occurrence of a second driver-negative primary lung adenocarcinoma in a non-smoker and underscores the importance of integrated histopathological, immunohisto chemical, and targeted molecular evaluation in distinguishing primary tumors from metastases, as well as the potential role of post-therapeutic carcinogenesis.

In this Romanian single-center cohort, pCR was independently predicted by clinical subtype and a limited set of biological variables, in line with contemporary literature. Although baseline patient-reported outcomes did not improve prediction of pathological response, the high prevalence of pre-treatment anxiety and the emergence of clinical depression during NAC argue for systematic psychosocial screening as part of standard neoadjuvant care.

These challenges include the need for preimplantation genetic testing for monogenic disorders (PGT-M) to reduce the risk of transmitting cancer-predisposition gene mutations to their offspring and the consideration of a gestational carrier, as current guidelines prohibit pregnancy during targeted molecular therapy. Maintaining a normal ovarian reserve would allow the opportunity to delay in vitro fertilization (IVF) until a more optimal time, thereby improving reproductive planning for patients who already manage the burdens of hereditary cancer syndrome.

External validation further confirmed the excellent discriminatory ability of the model, yielding an AUC value of 0.961 (P<0.001), sensitivity of 1.000 and specificity was 0.875. Overall, this nomogram, which integrates multiple clinically relevant factors, may serve as a useful tool for predicting post-NAT pCR in patients with HER2-positive BC and may support more precise treatment decision-making in clinical practice.

Exposure to As(III) markedly enhanced EGF-dependent phosphorylation of EGFR and showed a tendency to increase phosphorylation of the downstream signaling molecule ERK; however, sialidase treatment completely abolished this enhancement. Taken together, these results demonstrate that As(III) activates the EGF-induced phosphorylation cascade by promoting EGFR sialylation.

HR-pQCT was superior to DXA in detecting microarchitectural deterioration in women with breast cancer. This pilot study emphasizes the need for larger prospective studies in Indian cohorts.

Ribociclib-induced vitiligo-like depigmentation is an under-recognized adverse effect. Early recognition and multidisciplinary management are key to optimizing oncologic care without compromising therapeutic benefit.

The HER2CLIMB trial demonstrated the benefit of tucatinib, trastuzumab and capecitabine (TTC) in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC). Treatment discontinuation due to toxicity occurred in 7.4% of participants; there were no treatment-related deaths. In this national real-world cohort, TTC demonstrated clinically meaningful activity and was not associated with any new safety signals in HER2-positive ABC, including patients previously exposed to T-Dxd and those with brain metastases.

No statistically significant differences in ORR were detected according to prior CDK4/6 inhibitor exposure, number of prior treatment lines, or study design; however, these findings should be interpreted cautiously given the limited number of studies and substantial heterogeneity. Within a continuously evolving treatment landscape, further prospective studies are warranted to better define the optimal positioning of SG.

We further introduce a CAR incorporating an immunoglobulin G (IgG) Fc domain that recruits host Fc receptor-expressing phagocytes, enables T cell priming across major histocompatibility complex (MHC) mismatch, and enhances efficacy in immunocompetent allogeneic cancer models. Together, these findings establish expandable GMPs as a scalable platform for engineered immunotherapy.

NIR autofluorescence enables non-invasive, real-time assessment of kidney injury without external agents. This approach has immediate applications for longitudinal monitoring in preclinical research demonstrating proof-of-concept for future development of clinically applicable imaging approaches.